Systemic Sclerosis Associated Interstitial Lung Disease Clinical Trials

9 clinical trials for Systemic Sclerosis Associated Interstitial Lung Disease across international registries, including 2 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease — RECRUITING · PHASE2
• A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease — RECRUITING · PHASE2
• Systemic sclerosis associated interstitial lung disease: A longitudinal observational study assessing optimum treatment regimens. — COMPLETED · PHASE4
• A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD) — TERMINATED · PHASE3
• Exploratory, non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFRß) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) — NOT_YET_RECRUITING · PHASE1
• A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis — ACTIVE_NOT_RECRUITING
• "Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis" — OTHER
• Abituzumab in SSc-ILD — TERMINATED · PHASE2
• Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease — OTHER · PHASE3

Refine this search